Frank Pallone actually said...

"I do worry that it is important in the case of biosimilars or generics that that continue to be a way of reducing drug pricing."

"Biosimilars hold enormous potential to offer patients with serious and life-threatening diseases access to more treatment options and potentially lower cost options."

"I supported the creation of the pathway for biosimilars and for empowering FDA with the authority and resources to ensure that biosimilars are safely available here in the United States for the patien..."

"This is an important hearing, not only in terms of what is happening to biosimilars, but just the larger issue of drug pricing."